BAMEA-O16B
目录号 : GC62711
BAMEA-O16B 是一种脂质纳米颗粒。BAMEA-O16B 结合了二硫键，可以有效地将 Cas9 mRNA 和 sgRNA 传递到细胞中，同时响应细胞内还原环境释放 RNA 进行基因组编辑。BAMEA-O16B 可用于基因编辑的研究。
Cas No.:2490668-30-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BAMEAO16B is a lipid nanoparticle. BAMEAO16B integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing. BAMEAO16B can be used for the research of gene editing[1].
BAMEA-O16B/Cas9 mRNA/sgHPV18 (HeLa cells) treatment significantly prohibits HeLa growth compared to that of a scramble sgRNA and Cas9 mRNA delivery. BAMEA-O16B shows RNA delivery efficiency. BAMEA-O16B shows mRNA encapsulation efficiency. BAMEA-O16B shows GFP knockout efficiency. BAMEA-O16B mediated Cas9mRNA delivery is able to regulate endogenous gene expression. BAMEA-O16B/RNA treated cells shows a higher endosome escape efficiency than that of BAMEA-O16/RNA treatment. BAMEA-O16B/RFP mRNA (HeLa cells) nanoparticles results in efficient RFP expression[1].
BAMEA-O16B/Cas9 mRNA/sgRNA (I.v.) nanoparticle effectively knocks mouse serum proprotein convertase subtilisin/kexin type 9 (PCSK9) level down to 20% of nontreated mouse. BAMEA-O16B/Cas9 mRNA/sgPCSK9 nanoparticle reduces mouse serum PCSK9 down to 20% of that with DPBS injection or BAMEA-O16B/Cas9 mRNA/scramblesgRNA nanoparticle injections[1].
[1]. Liu J, et al. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. Adv Mater. 2019;31(33):e1902575.
| Cas No. | 2490668-30-7 | SDF | |
| 分子式 | C56H111N3O6S6 | 分子量 | 1114.89 |
| 溶解度 | Ethanol : 100 mg/mL (89.69 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8969 mL | 4.4847 mL | 8.9695 mL |
| 5 mM | 0.1794 mL | 0.8969 mL | 1.7939 mL |
| 10 mM | 0.0897 mL | 0.4485 mL | 0.8969 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles
Adv Mater 2019 Aug;31(33):e1902575.PMID:31215123DOI:PMC6732788
A main challenge to broaden the biomedical application of CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat (CRISPR) associated protein 9) genome editing technique is the delivery of Cas9 nuclease and single-guide RNA (sgRNA) into the specific cell and organ. An effective and very fast CRISPR/Cas9 genome editing in vitro and in vivo enabled by bioreducible lipid/Cas9 messenger RNA (mRNA) nanoparticle is reported. BAMEA-O16B, a lipid nanoparticle integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing as fast as 24 h post mRNA delivery. It is demonstrated that the simultaneous delivery of Cas9 mRNA and sgRNA using BAMEA-O16B knocks out green fluorescent protein (GFP) expression of human embryonic kidney cells with efficiency up to 90%. Moreover, the intravenous injection of BAMEA-O16B/Cas9 mRNA/sgRNA nanoparticle effectively accumulates in hepatocytes, and knocks down proprotein convertase subtilisin/kexin type 9 level in mouse serum down to 20% of nontreatment. The leading lipid nanoparticle, BAMEA-O16B, represents one of the most efficient CRISPR/Cas9 delivery nanocarriers reported so far, and it can broaden the therapeutic promise of mRNA and CRISPR/Cas9 technique further.